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months from index date were identified. ADs were categorized as tricyclic antide-
pressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and new antide-
pressants (NADs). The adherence measures of AD therapy include 90-days medi-
cation possession ratio (MPR, 75% as nonadherent), persistence (duration of
uninterrupted therapy 90 dayswith 14-day permissible gap), and switching of AD
class within 180-days were used. Relapse was defined as hospitalization or emer-
gency department visit due to depression, suicide attempts, or reinitiation of AD
therapy after at least 6 months from previous AD treatment. Cox proportional
hazards model was used to estimate risk ratios of relapse with 95% confidence
intervals for each adherencemeasure. RESULTS:A total of 88,079 patients satisfied
the selection criteria, among which mean age of 45.2 years and 67.3% of women.
Overall relapse rate was 29.5%. Adherence (MPR75%) or persistence (duration of
uninterrupted therapy 90 days) showed non-significant estimates of relapse risk
(aRR0.99[0.97-1.02] and 1.01[0.97-1.04], respectively). Patients who switched AD
class within 180 days showed increased risk of relapse (aRR1.18[1.15-1.21]).
CONCLUSIONS: Various definitions of adherence led to different estimates of re-
lapse rate. Diverse aspects of adherence should be considered when studying the
association between the medication adherence and clinical outcomes.
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OBJECTIVES: The Patient Health Questionnaire-4 (PHQ-4; Kroenke, 2009) is a com-
posite instrument constructed from the GAD-2 and PHQ-2 questionnaire assess-
ments of depression and anxiety symptoms.We sought to build on prior validation
of the instrument by evaluating the reproducibility of the PHQ-4 and testing equiv-
alence between paper and electronic administrationmodes.METHODS:The PHQ-4
and other questionnaire measures were administered to a sample of adults re-
cruited through newspaper and web-based advertisements in eight US cities. Par-
ticipants were randomized to complete the PHQ-4 on either paper or computerized
format. A one-week retest was completed at home. Reproducibility and mode
equivalence were assessed using the intraclass correlation coefficient (ICC). Cron-
bach’s alpha was calculated to assess internal consistency. To assess convergent
validity, the correlation of the PHQ-4 to theMental Component Subscore (MCS) and
the Mental Health Index (MHI-5) of the SF-36 was calculated. T-tests were used to
assess the difference in PHQ scores by participants’ self-reported prior diagnosis of
clinical depression. RESULTS: Of the 258 participants that completed baseline as-
sessment, 251 (97%) completed the one-week retest. The mean age of participants
was 48.6 years, 61% were female, and 71% were Caucasian. About half (n130;
50.4%) reported a prior depression diagnosis. The mean PHQ-4 score was 4.0(3.3),
and the ICC between paper and computerized administration was 0.86. The ICC for
the one-week retest was 0.88, and the PHQ-4 was found to be internally consistent
(Cronbach’s alpha0.90). Significant correlations were found with the MCS
(r0.79; p0.001) and the MHI-5 (r0.86; p0.001), and the instrument discrim-
inated between participants with and without prior depression diagnoses (mean
PHQ-4 scores of 5.8 vs. 2.1, p0.001). CONCLUSIONS: The PHQ-4 was observed to
have adequate reproducibility and internal consistency; appropriate convergent
validity; and significantly discriminates between participants with prior diagnoses
of depression. Equivalence between paper and web-based administration was
demonstrated.
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OBJECTIVES: Sample size determination is critical in planning psychometric stud-
ies in order to achieve stable results. Confirmatory factor analysis (CFA) is an es-
sential aspect of content validation and for psychometric studies. The current
study reviewed three approaches for CFA-based power analyses: N:q rule-of-
thumb (N:q), RMSEA-based sample size (RMSEA-BSS), and Monte Carlo simulation
(MC). METHODS: N:q states 10 (reliable loadings) or 20 participants (less reliable
loadings) are required for every free parameter. RMSEA-BSS uses the sampling
distribution of RMSEA to determine the power of a CFA for a predicted level of
RMSEAversus a given RMSEA criterion (similar to the power of a t-test for onemean
versus another). the MC is used to investigate the performance of statistical esti-
mators under various conditions wherein data are generated for over k10,000
simulated datasets to understand the sampling distributions of various parame-
ters. MC has many benefits, including statistical estimates of the sample size re-
quirements for a very specific CFAmodel. These three approaches were examined
on the CFA for a common 10-itemdepression instrument. RESULTS: For n:Q, a total
of 22 free parameters were present, thereby requiring between 220 or 440 subjects.
RMSEA-BSS was calculated using a free website (people.ku.edu/preacher/rmsea/
rmsea.htm), resulting in a sample size estimate of 283 (alpha0.05, CFA df31,
power0.8, RMSEA criterion0.06, andRMSEAestimate0.02). A sample size of 183
was calculated using MC. CONCLUSIONS:N:q is simple yet the least accurate tech-
nique used. The RMSEA-BSS approach is not as accurate nor as flexible as MC, nor
as quick as N:q. It is accessible to most psychometricians, however, and often
provides sufficient accuracy. The MC is sophisticated and highly accurate; it can
include almost any latent modeling variant, thereby allowing for excellent speci-
ficity, its only downside is its complexity. The current CFA inMCprovided amarked
savings in sample size.
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OBJECTIVES: To evaluate the performance of two instrument variables, namely
physician and nursing home facility preference, to examine the risk of death in
dual eligible elderly nursing home residents using antipsychotic agents.
METHODS: A retrospective cohort design involving dual eligible nursing home
residents 65 years and above was used. An instrumental variable analysis was
conducted to evaluate the risk of mortality within 180 days of antipsychotic expo-
sure. The physician’s preference was operationalized based on the most recent
antipsychotic prescription initiated by the physician. Nursing home facility pref-
erence was defined as the most frequently initiated antipsychotic agent in the
nursing home. The performance of each instruments was evaluated based on the
strength of association, covariate balance, and explanatory power in addition to
endogeneity tests. The risk of deathwasmodeled using extended Cox Proportional
Hazardmodel based on two-stage residual inclusionmethod for instrumental vari-
able analysis. RESULTS: Physician preference [Odd Ratio (OR) 3.97] and nursing
home facility preference (OR 4.54) were strongly associatedwith antipsychotic use.
The explanatory power in the multivariate models and covariate balance in the
preference groupswere similar with both instruments. Instrumental variable anal-
ysis involving physician preference, however, did not meet the criteria for endoge-
neity (Wu-Hausman F  1.49, P  0.22). Using nursing home facility preference as
an instrument, the extended Cox model revealed that risk of death is greater
among typical antipsychotic users in the initial 40 days [Hazard Ratio (HR) 2.76, 95%
CI 2.11-3.62] but decreases after 40 days [HR 1.44, 95% CI 1.10-1.88] when compared
to atypical users. CONCLUSIONS: Nursing home facility preference appears to be
valid instrument in the nursing home population. Evaluation of instruments is
critical in implementing instrumental variable analysis for pharmacoepidemiology
research.
PMH85
A SCHIZOPHRENIA OR BIPOLAR TYPE I DISORDER REGISTRY: LESSONS
LEARNED FROM CONDUCTING A REGISTRY STUDY WITH SAFETY NET
PROVIDERS
Panish J1, Dirani R2, Mark T3, Montejano LB4, Starr HL1, Mao L1
1Johnson & Johnson, Titusville, NJ, USA, 2Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville,
NJ, USA, 3Thomson Reuters, Washington, DC, USA, 4Thomson Reuters, Cambridge, MA, USA
OBJECTIVES: Registries are increasingly used to collect information on effective-
ness of new medications in real-world practice settings. Conducting a registry
study focused on providers who treat vulnerable populations and have limited
research experience can present unique challenges. The Research and Evaluation
of Antipsychotic Treatment in Community Behavioral Health Organizations OUT-
comes (REACHOUT) Registry is a naturalistic, longitudinal study of patients receiv-
ing primary treatment at community behavioral health organizations (CBHOs) to
provide information on paliperidone palmitate, risperidone long-acting therapy,
and other antipsychotics. This presentation discusses lessons learned thus far
from the REACH OUT study.METHODS: REACH OUT recruits patients with schizo-
phrenia or bipolar type I disorder from multiple CBHOs in the United States. Pa-
tients are identified by treating clinicians and screened by research coordinators to
determine eligibility. A Web-based data collection tool is used to enter data ob-
tained from patient self-reports, interviewer/clinician assessments, and medical
records abstraction. Patients will be followed for 1 year with assessments at base-
line, 6 months, and 12 months. RESULTS: Lessons learned thus far are 1) the value
of collaborating with the providermember organization to recruit sites; 2) the need
for buy-in from site management; 3) the importance of identifying dedicated staff
committed to research endeavors; 4) the importance of selection of instruments
that balance data collection burden and the desire for a variety of outcome mea-
sures; 5) benefits of vetting the draft protocol with potential sites to assess feasi-
bility; and 6) the importance of working with sites to address individual needs (e.g.,
local internal review board approval). CONCLUSIONS: Registry studies focusing on
patients treated by safety net providers, often with limited research experience,
require unique considerations. Working closely with sites up-front and obtaining
buy-in from site management and research staff have been crucial to REACH OUT
thus far.
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OBJECTIVES: Co-prescription of anticholinergic drugs with the traditional cholin-
esterase inhibitors treatment in patients suffering fromAlzheimer’s disease (AD) is
not recommended. Yet the extent of anticholinergic drugs use is unknown. Con-
versely, the prescription of anticholinergic drugs is not contraindicated with the
N-Methyl-D-Aspartic acid (NMDA) receptor antagonist. This study evaluates the
pattern of usage of drugs with anticholinergic activity in geriatric patients with AD
receiving cholinesterase inhibitors and NMDA receptor antagonist.METHODS: 654
patients suffering from AD above the age of 65 years were analyzed from NNHS
2004. The co-prescribed anticholinergic drugs were given a score of 0 to 3 using the
Clinician-Rated Anticholinergic Drug Scale with values ranging from no, mild,
A201V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
